Killer Cells, Lymphokine-Activated
Research News and Information

Sunday, November 22, 2009

Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.

24 Jul 2009 OBJECTIVE: Cord blood (CB) is limited by the absence of available donor effector cells for post-unrelated CB transplantation adoptive cellular immunotherapy. We reported the ability to ex vivo expand (EvE) CB mononuclear cells (MNC) after short-term ... Read more...

Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.

30 May 2009 As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined ... Read more...

Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus.

30 May 2009 OBJECTIVE: To determine the cytotoxicity of natural killer (NK) cells and the level of differentiation of hematopoietic stem cells (HSCs) into NK cells in systemic lupus erythematosus (SLE). METHODS: Patients with SLE (n=108), rheumatoid arthritis ... Read more...

Latest indexed articles for 'Killer Cells, Lymphokine-Activated'

These are the very latest articles for this heading:

• Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. 24 Jul 2009
• Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. 30 May 2009
• Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. 30 May 2009
• Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. 2 May 2009
• The CD8+population of LAK cells can lyse both HLA-positive and HLA-negative cancer cell lines. 29 Apr 2009
• Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. 29 Apr 2009
• A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. 30 Mar 2009
• Bovine natural killer cells. 3 Mar 2009
• Long-term outcome of immunotherapy for patients with refractory pancreatic cancer. 27 Feb 2009
• Significant impairment in immune recovery after cancer treatment. 27 Feb 2009
• Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. 30 Jan 2009
• Expression of CD40 by the cells of benign and malignant breast tumors and antitumor action of autologous lymphocytes against chemoresistant and chemosensitive tumors. 29 Nov 2008
• Immuno-modulatory effects of relaxation training and guided imagery in women with locally advanced breast cancer undergoing multimodality therapy: a randomised controlled trial. 10 Nov 2008
• Comment on "Molecular basis of the dual functions of 2B4 (CD244)". 13 Oct 2008
• Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. 29 Sep 2008
• Immunosensitization with a Bcl-2 small molecule inhibitor. 18 Sep 2008
• Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. 9 Sep 2008
• CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. 13 Aug 2008
• Continuous engagement of a self-specific activation receptor induces NK cell tolerance. 5 Jul 2008
• Endolymphatic immunotherapy in inoperable hepatocellular carcinoma. 29 Jun 2008

See a longer list of these articles.

Technical information about 'Killer Cells, Lymphokine-Activated'

Definition: Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.

Descriptor UI: D015979

Alternative terms: Killer Cells, Lymphokine-Activated; Cell, Lymphokine-Activated Killer; Cells, Lymphokine-Activated Killer; Killer Cell, Lymphokine-Activated; Killer Cells, Lymphokine Activated; Lymphokine-Activated Killer Cell; Lymphokine-Activated Killer Cells; Lymphokine Activated Killer Cells; LAK Cells; Cell, LAK; Cells, LAK; LAK Cell;

Related Mesh Headings: Interleukin-2; Immunotherapy, Adoptive;

Allowable Qualifiers: classification; cytology; drug effects; enzymology; immunology; metabolism; microbiology; parasitology; pathology; physiology; radiation effects; radiography; radionuclide imaging; secretion; transplantation; ultrastructure; ultrasonography; chemistry; virology;

Tree Number: A11.118.637.555.283.500; A11.118.637.555.567.537.500; A15.145.229.637.555.283.500; A15.145.229.637.555.567.537.500; A15.382.490.555.283.500; A15.382.490.555.567.537.500;

History Note: 90

Technical Notes: if subpopulations are discussed, coordinate IM with LYMPHOCYTE SUBSETS (IM)